Matches in SemOpenAlex for { <https://semopenalex.org/work/W2600341709> ?p ?o ?g. }
- W2600341709 endingPage "585" @default.
- W2600341709 startingPage "573" @default.
- W2600341709 abstract "Introduction: Immune check-point inhibitors are now employed as single-agents in current practice for the treatment of advanced non-small cell lung cancer (NSCLC), while combinations of different inhibitors are being evaluated in clinical trials. Although the safety profile of these compounds, with particular reference to drugs targeting programmed death protein 1 (PD-1) and its ligand (PD-L1), is generally considered manageable, peculiar, immune-related toxicities may onset.Areas covered: This review focuses on the immune-related adverse events (irAEs) observed during immune check-point blockade in NSCLC and their management. The authors report the incidence of irAEs based on the currently available data involving NSCLC and provide recommendations on the general approach to irAEs, as well as indications for the most relevant site-specific events.Expert opinion: Since irAEs may involve a wide range of organs and systems and are potentially reversible if promptly treated, early diagnosis should always be achieved; this might be particularly challenging when other potential causes of toxicity are suspected, such as infections or concurrent treatments. Finally, drugs active on the PD-1/PD-L1 axis appear to be generally manageable even when they are administered to patients with relevant comorbidities, provided that adequate clinical monitoring is performed." @default.
- W2600341709 created "2017-04-07" @default.
- W2600341709 creator A5025818974 @default.
- W2600341709 creator A5032477448 @default.
- W2600341709 creator A5035375963 @default.
- W2600341709 creator A5043174098 @default.
- W2600341709 creator A5073079268 @default.
- W2600341709 creator A5074054015 @default.
- W2600341709 creator A5086247944 @default.
- W2600341709 date "2017-04-19" @default.
- W2600341709 modified "2023-10-16" @default.
- W2600341709 title "Releasing the brake: safety profile of immune check-point inhibitors in non-small cell lung cancer" @default.
- W2600341709 cites W1556990476 @default.
- W2600341709 cites W1898612748 @default.
- W2600341709 cites W1913801405 @default.
- W2600341709 cites W1966618770 @default.
- W2600341709 cites W1967980487 @default.
- W2600341709 cites W1972728281 @default.
- W2600341709 cites W1982488143 @default.
- W2600341709 cites W1983050041 @default.
- W2600341709 cites W2022073464 @default.
- W2600341709 cites W2029073555 @default.
- W2600341709 cites W2033009850 @default.
- W2600341709 cites W2048296690 @default.
- W2600341709 cites W2066671159 @default.
- W2600341709 cites W2074557796 @default.
- W2600341709 cites W2080759679 @default.
- W2600341709 cites W2104347254 @default.
- W2600341709 cites W2105057287 @default.
- W2600341709 cites W2106511606 @default.
- W2600341709 cites W2107484016 @default.
- W2600341709 cites W2110773108 @default.
- W2600341709 cites W2116607009 @default.
- W2600341709 cites W2119198740 @default.
- W2600341709 cites W2128362832 @default.
- W2600341709 cites W2139192665 @default.
- W2600341709 cites W2140521865 @default.
- W2600341709 cites W2152194859 @default.
- W2600341709 cites W2156353875 @default.
- W2600341709 cites W2158425309 @default.
- W2600341709 cites W2164838411 @default.
- W2600341709 cites W2198093519 @default.
- W2600341709 cites W2201460159 @default.
- W2600341709 cites W2216290707 @default.
- W2600341709 cites W2259730793 @default.
- W2600341709 cites W2260067559 @default.
- W2600341709 cites W2263759961 @default.
- W2600341709 cites W2265285917 @default.
- W2600341709 cites W2278440281 @default.
- W2600341709 cites W2292835392 @default.
- W2600341709 cites W2293531514 @default.
- W2600341709 cites W2298823224 @default.
- W2600341709 cites W2301027955 @default.
- W2600341709 cites W2310054409 @default.
- W2600341709 cites W2323655202 @default.
- W2600341709 cites W2325469667 @default.
- W2600341709 cites W2342436929 @default.
- W2600341709 cites W2343059010 @default.
- W2600341709 cites W2344489622 @default.
- W2600341709 cites W2365295390 @default.
- W2600341709 cites W2367690016 @default.
- W2600341709 cites W2397678426 @default.
- W2600341709 cites W2411868251 @default.
- W2600341709 cites W2441690768 @default.
- W2600341709 cites W2464620827 @default.
- W2600341709 cites W2466250207 @default.
- W2600341709 cites W2467224355 @default.
- W2600341709 cites W2468576628 @default.
- W2600341709 cites W2469157980 @default.
- W2600341709 cites W2471699783 @default.
- W2600341709 cites W2478423423 @default.
- W2600341709 cites W2486996368 @default.
- W2600341709 cites W2501357434 @default.
- W2600341709 cites W2502096301 @default.
- W2600341709 cites W2503552011 @default.
- W2600341709 cites W2508205285 @default.
- W2600341709 cites W2508623887 @default.
- W2600341709 cites W2510390828 @default.
- W2600341709 cites W2513176323 @default.
- W2600341709 cites W2517761860 @default.
- W2600341709 cites W2521641698 @default.
- W2600341709 cites W2521728442 @default.
- W2600341709 cites W2522875140 @default.
- W2600341709 cites W2525217971 @default.
- W2600341709 cites W2527905628 @default.
- W2600341709 cites W2530468309 @default.
- W2600341709 cites W2536144887 @default.
- W2600341709 cites W2547133566 @default.
- W2600341709 cites W2549589051 @default.
- W2600341709 cites W2550815089 @default.
- W2600341709 cites W2551653151 @default.
- W2600341709 cites W2557098519 @default.
- W2600341709 cites W2560704457 @default.
- W2600341709 cites W2564183539 @default.
- W2600341709 cites W2565234466 @default.
- W2600341709 cites W2565782504 @default.
- W2600341709 cites W2565826521 @default.
- W2600341709 cites W2567564314 @default.